Analysis of posttransplant risk factors for the development of TA-TMA
Variables . | Univariate . | Multivariate . | ||
---|---|---|---|---|
HR (95% CI) . | P . | HR (95% CI) . | P . | |
Grade 3-4 aGVHD | ||||
N | Reference | Reference | ||
Y | 4.62 (2.98-7.14) | <.01* | 4.02 (2.36-6.83) | <.01* |
Bacterial infection | ||||
N | Reference | |||
Y | 1.1 (0.81-1.74) | .37 | ||
Aspergillus infection | ||||
N | Reference | Reference | ||
Y | 2.41 (1.32-4.39) | <.01* | 2.29 (1.15-4.54) | .01* |
Candida infection | ||||
N | Reference | |||
Y | 1.36 (0.43-4.30) | .60 | ||
CMV infection | ||||
N | Reference | |||
Y | 1.57 (0.64-3.76) | .32 | ||
CMV reactivation | ||||
N | Reference | Reference | ||
Y | 2.01 (1.31-3.09) | <.01* | 1.51 (0.92-2.47) | .09 |
Hemorrhagic cystitis | ||||
N | Reference | Reference | ||
Y | 1.91 (1.00-3.64) | .05 | 1.45 (0.69-3.07) | .32 |
VOD/SOS | ||||
N | Reference | Reference | ||
Y | 6.39 (3.66-11.1) | <.01* | 4.47 (2.25-8.87) | <.01* |
Variables . | Univariate . | Multivariate . | ||
---|---|---|---|---|
HR (95% CI) . | P . | HR (95% CI) . | P . | |
Grade 3-4 aGVHD | ||||
N | Reference | Reference | ||
Y | 4.62 (2.98-7.14) | <.01* | 4.02 (2.36-6.83) | <.01* |
Bacterial infection | ||||
N | Reference | |||
Y | 1.1 (0.81-1.74) | .37 | ||
Aspergillus infection | ||||
N | Reference | Reference | ||
Y | 2.41 (1.32-4.39) | <.01* | 2.29 (1.15-4.54) | .01* |
Candida infection | ||||
N | Reference | |||
Y | 1.36 (0.43-4.30) | .60 | ||
CMV infection | ||||
N | Reference | |||
Y | 1.57 (0.64-3.76) | .32 | ||
CMV reactivation | ||||
N | Reference | Reference | ||
Y | 2.01 (1.31-3.09) | <.01* | 1.51 (0.92-2.47) | .09 |
Hemorrhagic cystitis | ||||
N | Reference | Reference | ||
Y | 1.91 (1.00-3.64) | .05 | 1.45 (0.69-3.07) | .32 |
VOD/SOS | ||||
N | Reference | Reference | ||
Y | 6.39 (3.66-11.1) | <.01* | 4.47 (2.25-8.87) | <.01* |
Multivariate analysis was performed including significant pre-HSCT factors (age, PS, HCT-CI, donor source, and HLA mismatch).
Statistically significant.